CoChat

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic colorectal cancer (CRC). The present exploratory biomarker analysis aims to investigate relationships between biomarkers and clinical outcomes in patients with HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+ and in situ hybridization [ISH] positive) Cohort A (N = 53) of DESTINY-CRC01. Higher levels of HER2 biomarkers in baseline tissue and liquid biopsies, including HER2 status (IHC/ISH), HER2/CEP17 ratio, HER2 ISH signals, HER2 H-score, plasma HER2 (ERBB2) amplification status, HER2 adjusted plasma copy number, and HER2 extracellular domain correlate with antitumor activity (indicated by objective response rate, progression-free survival, and overall survival) of T-DXd. Baseline circulating tumor DNA (ctDNA) analysis suggests antitumor activity of T-DXd in patients who had baseline activating RAS, PIK3CA, or HER2 mutations detected in ctDNA. The phase 2 trial, DESTINYCRC01, previously demonstrated durable activity of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic colorectal cancer refractory to standard treatment. Here, the authors report the exploratory analysis of the DESTINY-CRC01 trial investigating markers of response or resistance to T-DXd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-53223-3

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Biomarker analysis sets. aNo somatic mutation detected. C, cycle; ctDNA, circulating tumor DNA; D, day; EOT, end of treatment; HER2ECD, human epidermal growth factor receptor 2 extracellular domain.
Fig. 1 Biomarker analysis sets. aNo somatic mutation detected. C, cycle; ctDNA, circulating tumor DNA; D, day; EOT, end of treatment; HER2ECD, human epidermal growth factor receptor 2 extracellular domain.CC BY-NC-ND · PubMed Central
Fig. 2 Antitumor activity of T-DXd as best percentage change from baseline in sum of tumor diameters according to ctDNA genomic landscape at baseline. Waterfall plot shows the best percentage change in the sum of diameters from baseline, amplifications and mutations of CRC-related genes, bTMB status, histological grade, and primary tumor site. Amplification type was reported from Guardant Health. HER2 gain-of-function mutations were selected based on OncoKB; RAS: mutation at codon 12, 13, 59, 61, 117, or 146. PIK3CA mutation was selected according to previous publication34; PTEN: loss-of-function mutations were selected based on OncoKB. bTMB of ≥ 20 mut/Mb was considered high based on the Guardant Health report. Of 4 patients with evaluable ctDNA data and no data available for best percentage change in the sum of diameters, 2 had focal HER2 plasma amplification, 2 had aneuploidy HER2 plasma amplification, none had HER2 mutation, 1 had RAS mutation, 2 had PIK3CA mutation, 1 had PTEN mutation/loss, 2 had aneuploidy MET amplification, 3 had bTMB ≥ 20 mut/Mb, and 1 had bTMB < 20 mut/Mb. amp, amplification; bTMB, blood tumor mutational burden; ctDNA, circulating tumor DNA; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; mut, mutation.
Fig. 2 Antitumor activity of T-DXd as best percentage change from baseline in sum of tumor diameters according to ctDNA genomic landscape at baseline. Waterfall plot shows the best percentage change in the sum of diameters from baseline, amplifications and mutations of CRC-related genes, bTMB status, histological grade, and primary tumor site. Amplification type was reported from Guardant Health. HER2 gain-of-function mutations were selected based on OncoKB; RAS: mutation at codon 12, 13, 59, 61, 117, or 146. PIK3CA mutation was selected according to previous publication34; PTEN: loss-of-function mutations were selected based on OncoKB. bTMB of ≥ 20 mut/Mb was considered high based on the Guardant Health report. Of 4 patients with evaluable ctDNA data and no data available for best percentage change in the sum of diameters, 2 had focal HER2 plasma amplification, 2 had aneuploidy HER2 plasma amplification, none had HER2 mutation, 1 had RAS mutation, 2 had PIK3CA mutation, 1 had PTEN mutation/loss, 2 had aneuploidy MET amplification, 3 had bTMB ≥ 20 mut/Mb, and 1 had bTMB < 20 mut/Mb. amp, amplification; bTMB, blood tumor mutational burden; ctDNA, circulating tumor DNA; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; mut, mutation.CC BY-NC-ND · PubMed Central
Fig. 3 Antitumor activity of T-DXd according to baseline HER2 biomarker status. Exploratory cutoff values for each HER2 biomarker were defined as the maximum value of the Youden index for ORR. Vertical red dashed line shows the ORR of 45.3% in the overall population for Cohort A. P values are based on two-sided Fisher’s exact test for ORR and those based on two-sided log-rank test for PFS and OS are shown, without adjustment for multiple comparisons. Error bars represent the 95% CI. The exact P values for HER2 H-score for OS, HER2 ISH signal for PFS, HER2 ApCN for PFS, and HER2 ApCN for OS were 0.000175, 0.000394, 0.0000168, and 0.0000991, respectively. Amp, amplification; ApCN, adjusted plasma copy number; HER2, human epidermal growth factor receptor 2; HER2ECD, human epidermal growth factor receptor 2 extracellular domain; IHC, immunohistochemistry; ISH, in situ hybridization; NA, not applicable; ND, not determined; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
Fig. 3 Antitumor activity of T-DXd according to baseline HER2 biomarker status. Exploratory cutoff values for each HER2 biomarker were defined as the maximum value of the Youden index for ORR. Vertical red dashed line shows the ORR of 45.3% in the overall population for Cohort A. P values are based on two-sided Fisher’s exact test for ORR and those based on two-sided log-rank test for PFS and OS are shown, without adjustment for multiple comparisons. Error bars represent the 95% CI. The exact P values for HER2 H-score for OS, HER2 ISH signal for PFS, HER2 ApCN for PFS, and HER2 ApCN for OS were 0.000175, 0.000394, 0.0000168, and 0.0000991, respectively. Amp, amplification; ApCN, adjusted plasma copy number; HER2, human epidermal growth factor receptor 2; HER2ECD, human epidermal growth factor receptor 2 extracellular domain; IHC, immunohistochemistry; ISH, in situ hybridization; NA, not applicable; ND, not determined; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.CC BY-NC-ND · PubMed Central
Fig. 4 Probability of PFS according to baseline HER2 biomarker status. The probability of PFS is shown according to HER2 IHC status (panel A) HER2 biomarkers based on exploratory cutoff values (panels B, C, D, F, G), and type of HER2 gene amplification (panel E). aExploratory cutoff values (panels B, C, D, F, G) were determined using receiver operating characteristics analysis: H-score cutoff = 240; HER2/CEP17 ratio cutoff = 6.30; HER2 ISH signal cutoff = 11.25; HER2 ApCN cutoff = 30.99; serum HER2ECD cutoff = 23.5 ng/mL. bAmplification type (panel E) was reported from Guardant Health. Amp, amplification; ApCN, adjusted plasma copy number; HER2, human epidermal growth factor receptor 2; HER2ECD, human epidermal growth factor receptor 2 extracellular domain; IHC, immunohistochemistry; ISH, in situ hybridization; mPFS, median progression-free survival; NA, not applicable; ND, not determined; PFS, progression-free survival.
Fig. 4 Probability of PFS according to baseline HER2 biomarker status. The probability of PFS is shown according to HER2 IHC status (panel A) HER2 biomarkers based on exploratory cutoff values (panels B, C, D, F, G), and type of HER2 gene amplification (panel E). aExploratory cutoff values (panels B, C, D, F, G) were determined using receiver operating characteristics analysis: H-score cutoff = 240; HER2/CEP17 ratio cutoff = 6.30; HER2 ISH signal cutoff = 11.25; HER2 ApCN cutoff = 30.99; serum HER2ECD cutoff = 23.5 ng/mL. bAmplification type (panel E) was reported from Guardant Health. Amp, amplification; ApCN, adjusted plasma copy number; HER2, human epidermal growth factor receptor 2; HER2ECD, human epidermal growth factor receptor 2 extracellular domain; IHC, immunohistochemistry; ISH, in situ hybridization; mPFS, median progression-free survival; NA, not applicable; ND, not determined; PFS, progression-free survival.CC BY-NC-ND · PubMed Central
Fig. 5 Antitumor activity of T-DXd according to mutation in PIK3CA, RAS, and HER2 in ctDNA at baseline and bTMB. Vertical red dashed line shows the ORR of 45.3% in the overall population for Cohort A. P values are based on two-sided Fisher’s exact test for ORR and those based on two-sided log-rank test for PFS and OS are shown, without adjustment for multiple comparisons. Error bars represent the 95% CI. PIK3CA variants were determined according to published data34. NRAS and KRAS variants were determined as mutation at codon 12, 13, 59, 61, 117, or 146. bTMB ≥ 20 mut/Mb was considered high according to the Guardant Health report. bTMB, blood tumor mutational burden; Mut, mutant; NA, not applicable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; WT, wild type.
Fig. 5 Antitumor activity of T-DXd according to mutation in PIK3CA, RAS, and HER2 in ctDNA at baseline and bTMB. Vertical red dashed line shows the ORR of 45.3% in the overall population for Cohort A. P values are based on two-sided Fisher’s exact test for ORR and those based on two-sided log-rank test for PFS and OS are shown, without adjustment for multiple comparisons. Error bars represent the 95% CI. PIK3CA variants were determined according to published data34. NRAS and KRAS variants were determined as mutation at codon 12, 13, 59, 61, 117, or 146. bTMB ≥ 20 mut/Mb was considered high according to the Guardant Health report. bTMB, blood tumor mutational burden; Mut, mutant; NA, not applicable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; WT, wild type.CC BY-NC-ND · PubMed Central
Fig. 6 Probability of PFS according to mutation in PIK3CA, RAS, and HER2 in ctDNA at baseline. The probability of PFS is shown according to mutation in PIK3CA (panel A), RAS (panel B), or HER2 (panel C) genes. PIK3CA variants were determined according to published data34. NRAS and KRAS variants were determined as mutation at codon 12, 13, 59, 61, 117, or 146. mPFS, median progression-free survival; Mut, mutant; NA, not applicable; PFS, progression-free survival; WT, wild type.
Fig. 6 Probability of PFS according to mutation in PIK3CA, RAS, and HER2 in ctDNA at baseline. The probability of PFS is shown according to mutation in PIK3CA (panel A), RAS (panel B), or HER2 (panel C) genes. PIK3CA variants were determined according to published data34. NRAS and KRAS variants were determined as mutation at codon 12, 13, 59, 61, 117, or 146. mPFS, median progression-free survival; Mut, mutant; NA, not applicable; PFS, progression-free survival; WT, wild type.CC BY-NC-ND · PubMed Central
Fig. 7 Plasma HER2 amplification status at baseline and at disease progression. Analysis included 29 patients in Cohort A who discontinued T-DXd because of disease progression and had detectable ctDNA at C1D1 and at EOT. Responder/non-responder status was determined by blinded independent central review. Amp, amplification; C1D1, cycle 1, day 1; ctDNA, circulating tumor DNA; EOT, end of treatment.
Fig. 7 Plasma HER2 amplification status at baseline and at disease progression. Analysis included 29 patients in Cohort A who discontinued T-DXd because of disease progression and had detectable ctDNA at C1D1 and at EOT. Responder/non-responder status was determined by blinded independent central review. Amp, amplification; C1D1, cycle 1, day 1; ctDNA, circulating tumor DNA; EOT, end of treatment.CC BY-NC-ND · PubMed Central
Fig. 8 Acquired plasma ctDNA mutations at disease progression in patients with HER2-positive mCRC treated with T-DXd. Acquired refers to patients with acquired mutations detected only at disease progression. Lost refers to patients with mutations detected only at cycle 1, day 1. Maintained refers to patients with mutations at cycle 1, day 1, and at disease progression. bTMB, blood tumor mutational burden; CBOR, confirmed best overall response; ctDNA, circulating tumor DNA; HER2, human epidermal growth factor receptor 2; mCRC, metastatic colorectal cancer; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
Fig. 8 Acquired plasma ctDNA mutations at disease progression in patients with HER2-positive mCRC treated with T-DXd. Acquired refers to patients with acquired mutations detected only at disease progression. Lost refers to patients with mutations detected only at cycle 1, day 1. Maintained refers to patients with mutations at cycle 1, day 1, and at disease progression. bTMB, blood tumor mutational burden; CBOR, confirmed best overall response; ctDNA, circulating tumor DNA; HER2, human epidermal growth factor receptor 2; mCRC, metastatic colorectal cancer; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 31

Metadata

Authors
Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., Rodriguez, J., Chau, I., Di Bartolomeo, M., Kawakami, H., Suto, F., Koga, M., Inaki, K., Kuwahara, Y., Takehara, I., Barrios, D., Kobayashi, K., Grothey, A., & Yoshino, T.
Affiliations
  • University of Milan (IT)
  • The University of Texas MD Anderson Cancer Center (US)
  • Aichi Cancer Center (JP)
  • The Cancer Institute Hospital (JP)
  • Shikoku Cancer Center (JP)
  • Royal Marsden NHS Foundation Trust (GB)
  • Kindai University Hospital (JP)
  • Daiichi Sankyo (United States) (US)
  • Daiichi-Sankyo (Japan) (JP)
  • West Cancer Center (US)
  • National Cancer Center Hospital East (JP)
Corresponding author
Siena, Salvatore
Venue
Nature Communications
Published
2024-11-25
Volume
15
Issue
1
Pages
10213-10213
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4404672172
Cited by
30
References
31
Citations by year
2026: 15 · 2025: 15
FWCI
5.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Daiichi Sankyo
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
trastuzumab deruxtecan, HER2/CEP17 ratio, HER2 extracellular domain, circulating tumor DNA, RAS mutations, PIK3CA mutation, HER2 mutation, predictive biomarkers, treatment response, treatment resistance
MeSH terms
Trastuzumab, Circulating Tumor DNA, Antineoplastic Agents, Immunological, Progression-Free Survival, Adult, Aged, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Biomarkers, Tumor, Colorectal Neoplasms, Treatment Outcome, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. https://app.cochat.ai/papers/10.1038/s41467-024-53223-3
The paper
Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., Rodriguez, J., Chau, I., Di Bartolomeo, M., Kawakami, H., Suto, F., Koga, M., Inaki, K., Kuwahara, Y., Takehara, I., Barrios, D., Kobayashi, K., Grothey, A., & Yoshino, T. (2024). HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nature Communications. https://doi.org/10.1038/s41467-024-53223-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.